Discrimination of Potent Inhibitors of Toxoplasma gondii Enoyl-Acyl Carrier Protein Reductase by a Thermal Shift Assay

作者：Afanador Gustavo A; Muench Stephen P; McPhillie Martin; Fomovska Alma; Schoen Arne; Zhou Ying; Cheng Gang; Stec Jozef; Freundlich Joel S; Shieh Hong Ming; Anderson John W; Jacobus David P; Fidock David A; Kozikowski Alan P; Fishwick Cohn W; Rice David W; Freire Ernesto; McLeod Rima; Prigge Sean T^*

来源：Biochemistry, 2013, 52(51): 9155-9166.

DOI：10.1021/bi400945y

Many microbial pathogens rely on a type II fatty acid synthesis (FASII) pathway that is distinct from the type I pathway found in humans. Enoyl-acyl carrier protein reductase (ENR) is an essential FASII pathway enzyme and the target of a number of antimicrobial drug discovery efforts. The biocide triclosan is established as a potent inhibitor of ENR and has been the starting point for medicinal chemistry studies. We evaluated a series of triclosan analogues for their ability to inhibit the growth of Toxoplasma gondii, a pervasive human pathogen, and its ENR enzyme (TgENR). Several compounds that inhibited TgENR at low nanomolar concentrations were identified but could not be further differentiated because of the limited dynamic range of the TgENR activity assay. Thus, we adapted a thermal shift assay (TSA) to directly measure the dissociation constant (K-d) of the most potent inhibitors identified in this study as well as inhibitors from previous studies. Furthermore, the TSA allowed us to determine the mode of action of these compounds in the presence of the reduced nicotinamide adenine dinucleotide (NADH) or nicotinamide adenine dinucleotide (NAD(+)) cofactor. We found that all of the inhibitors bind to a TgENR-NAD(+) complex but that they differed in their dependence on NAD(+) concentration. Ultimately, we were able to identify compounds that bind to the TgENR-NAD(+) complex in the low femtomolar range. This shows how TSA data combined with enzyme inhibition, parasite growth inhibition data, and ADMET predictions allow for better discrimination between potent ENR inhibitors for the future development of medicine.

• 出版日期2013-12-24
• 单位rutgers